ABBVIE INC. vs. Alnylam Pharmaceuticals, Inc.
ABBVIE INC. (ABBV) comes out ahead, leading on 5 of 9 compared factors.
Size & Scale
| ABBV | ALNY | |
|---|---|---|
| Market Cap | $466.55 billion | $31.88 billion |
| Revenue (TTM) | $64.39 billion | $4.80 billion |
| Net Income (TTM) | $6.32 billion | $733.11 million |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | ALNY | |
|---|---|---|
| P/E Ratio | 74.71 | 44.57 |
| Price / Book | -79.24 | 23.54 |
| Price / Sales | 7.25 | 6.64 |
ALNY leads on 2 of 3 valuation factors.
Profitability
| ABBV | ALNY | |
|---|---|---|
| Net Margin | 9.81% | 15.26% |
| Return on Equity | -107.29% | 54.14% |
ALNY leads on 2 of 2 profitability factors.
Dividend
| ABBV | ALNY | |
|---|---|---|
| Dividend Yield | 2.62% | — |
| Payout Ratio | 195.48 | — |
ABBV and ALNY split the dividend factors evenly.
Risk & Sentiment
| ABBV | ALNY | |
|---|---|---|
| Short Interest | 0.85% | 4.32% |
ABBV leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, ALNY overview, ALNY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.